Validity of the ADHD module of the Mini International Neuropsychiatric Interview PLUS for screening of adult ADHD in treatment seeking substance use disorder patients: ADHD screening with MINI-Plus

Raul Felipe Palma-Álvarez; Csaba Barta; Pieter Jan Carpentier; Susan Carruthers; Cleo L Crunelle; Zsolt Demetrovics; Geert Dom; Stephen V Faraone; Johan Franck; Brian Johnson; Máté Kapitány-Fövény; Sharlene Kaye; Maija Konstenius; Frieda Matthys; Franz Moggi; Merete Møller; Arnt Schellekens; Arvid Skutle; Geurt van de Glind; Katelijne van Emmerik-van Oortmerssen; Sofie Verspreet; Robert A Schoevers; Sara Wallhed; Frances R Levin; Lara Grau-López; Miguel Casas; Wim van den Brink; Josep Antoni Ramos-Quiroga; IASP Research Group

doi:10.1016/j.rpsm.2020.04.013

Validity of the ADHD module of the Mini International Neuropsychiatric Interview PLUS for screening of adult ADHD in treatment seeking substance use disorder patients: ADHD screening with MINI-Plus

Rev Psiquiatr Salud Ment (Engl Ed). 2020 Jun 16;S1888-9891(20)30038-0. doi: 10.1016/j.rpsm.2020.04.013. Online ahead of print.

[Article in English, Spanish]

Authors

Raul Felipe Palma-Álvarez¹, Csaba Barta², Pieter Jan Carpentier³, Susan Carruthers⁴, Cleo L Crunelle⁵, Zsolt Demetrovics⁶, Geert Dom⁷, Stephen V Faraone⁸, Johan Franck⁹, Brian Johnson¹⁰, Máté Kapitány-Fövény¹¹, Sharlene Kaye¹², Maija Konstenius⁹, Frieda Matthys¹³, Franz Moggi¹⁴, Merete Møller¹⁵, Arnt Schellekens¹⁶, Arvid Skutle¹⁷, Geurt van de Glind¹⁸, Katelijne van Emmerik-van Oortmerssen¹⁹, Sofie Verspreet²⁰, Robert A Schoevers²¹, Sara Wallhed²², Frances R Levin²³, Lara Grau-López¹, Miguel Casas¹, Wim van den Brink²⁴, Josep Antoni Ramos-Quiroga²⁵; IASP Research Group

Affiliations

¹ Department of Psychiatry, Hospital Universitari Vall d'Hebron, Barcelona, Spain; Department of Psychiatry and Forensic Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.
² Institute of Medical Chemistry, Molecular Biology, Pathobiochemistry, Semmelweis University, Budapest, Hungary.
³ Reinier van Arkel mental health institute, 's-Hertogenbosch, The Netherlands.
⁴ National Drug Research Institute, Curtin University, Perth, Australia.
⁵ Department of Psychiatry, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium; Toxicological Center, Antwerp University, Antwerp, Belgium.
⁶ Institute of Psychology, ELTE Eötvös Loránd University, Budapest, Hungary.
⁷ Antwerp University (UA), Collaborative Antwerp Psychiatric Research Institute (CAPRI), Antwerp, Belgium; Psychiatric Center Mutiversum, Boechout, Belgium.
⁸ Departments of Psychiatry and of Neuroscience and Physiology, SUNY Upstate Medical Center, Syracuse, NY, USA.
⁹ Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
¹⁰ Departments of Psychiatry and of Anesthesia, SUNY Upstate Medical Center, Syracuse, NY, USA.
¹¹ Nyírő Gyula National Institute of Psychiatry and Addictions, Budapest, Hungary; Faculty of Health Sciences, Semmelweis University, Budapest, Hungary.
¹² National Drug and Alcohol Research Center, University of New South Wales, Sydney, Australia.
¹³ Department of Psychiatry, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.
¹⁴ University Hospital of Psychiatry and Psychotherapy, University of Bern, Switzerland.
¹⁵ Department for Substance Abuse Treatment, Østfold Hospital Trust, Norway.
¹⁶ Department of Psychiatry, Radboudumc, Donders Institute for Brain, Cognition and Behavior, Nijmegen Institute for Scientist Practitioners in Addiction (NISPA), Nijmegen, The Netherlands.
¹⁷ Bergen Clinics Foundation, Bergen, Norway.
¹⁸ ICASA Foundation, University of Amsterdam, Amsterdam, The Netherlands.
¹⁹ Arkin Mental Health and Addiction Treatment Center, Amsterdam, The Netherlands; University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
²⁰ Psychiatric Center Mutiversum, Boechout, Belgium.
²¹ University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
²² Stockholm Centre for Dependency Disorders, Sweden.
²³ Columbia University, the New York State Psychiatric Institute, New York, NY, USA.
²⁴ Amsterdam Institute for Addiction Research, Department of Psychiatry, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
²⁵ Department of Psychiatry, Hospital Universitari Vall d'Hebron, Barcelona, Spain; Department of Psychiatry and Forensic Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain. Electronic address: jaramos@vhebron.net.

PMID: 32561156
DOI: 10.1016/j.rpsm.2020.04.013

Abstract

Objective: This study aims to assess the validity of the ADHD module of the Mini-International Neuropsychiatric Interview (MINI-Plus) in patients with substance use disorders (SUD), using the Conners' Adult ADHD Diagnostic Interview for DSM-IV (CAADID) as the external criterion.

Method: A cross sectional international multi-center study in 10 countries was conducted in treatment seeking SUD patients. A sample of 1263 patients with both MINI-Plus and CAADID was analyzed to determine the psychometric properties of the MINI-Plus.

Results: According to the CAADID, 179 patients (14.2%) met criteria for adult ADHD, whereas according to the MINI-Plus 227 patients (18.0%) were identified as having adult ADHD. Sensitivity of the MINI-Plus ADHD module was 74%, specificity was 91%, positive predictive value was 60% and negative predictive value was 96%. Kappa was 0.60.

Conclusion: The MINI-Plus has acceptable criterion validity for the screening of adult ADHD in treatment seeking SUD patients.

Scientific significance: On the basis of the results, The MINI-Plus may be used for the screening of ADHD in SUD patients.

Keywords: ADHD; Comorbidity; Comorbilidad; MINI; Psicometría; Psychometrics; Substance use disorder; TDAH; Trastorno de consumo de sustancias.